

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
June 12, 2024
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 3:00 p.m. on Wednesday, June 12, 2024.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Edward Behling, MD
Cheryl Hartvigsen, RPh
Philip Mubarak, MD

Kelly Barth, DO
Divya Ahuja, MD
Garrett Whittle, PharmD

Duncan Norton, MD
Heather Hembree, PharmD

SC DHHS Staff:

Cheryl Anderson, RPh
Kevin Wessinger, MD
Kim Bristow, RPh
Brandie Crider, CPhT
Tawanna Ziegler, CPhT
Ashley Sirianni, DNP
Sarah Hearn-Bailey

Magellan Medicaid Admin:

Lisa Correll, PharmD
Blake Cook, RPh
Manisa Bulsara, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, March 28, 2024

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
J&J	Naji Brach, PharmD	Symtuza (HIV/AIDS)
Gilead	Desola Davis, PharmD	Biktarvy (HIV/AIDS)
Leo Pharma	Suzan Tsang, PharmD	Adbry (Atopic Dermatitis Immunomodulators)
Sanofi	Tenecia Talley, PharmD	Dupixent (Atopic Dermatitis Immunomodulators)
Rhythm Pharma	Cody L. Gerber, PharmD	Imcivree (Weight Management Agents)
Novo Nordisk	Jeff Goforth, PharmD	Wegovy (Weight Management Agents)

C. Drug Classes for Review

Classes for Review

HIV/AIDS

Atopic Dermatitis Immunomodulators, Injectable

Weight Management Agents, Injectable

Classes for Re-review

Angiotensin Receptor Blockers (ARBs)

The chart below represents the recommendations from the State:

HIV/AIDS	
Preferred	Non-Preferred
All oral agents are preferred including medications for PEP/PrEP ^{1*}	Fuzeon ²
<i>*HCP administered agents will continue to be covered via the Medical Benefit.</i>	
ATOPIC DERMATITIS IMMUNOMODULATORS, INJECTABLES	
Preferred	Non-Preferred
Adbry ^{®1**}	
Dupixent ^{®1**}	
WEIGHT MANAGEMENT AGENTS, INJECTABLES	
Preferred	Non-Preferred
Wegovy ^{®1**}	Saxenda ^{®2**}
ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	
Preferred	Non-Preferred
eprosartan tabs	Atacand [®]
irbesartan tabs	Diovan [®]
losartan tabs	Edarbi [®]

ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) (continued)	
Preferred	Non-Preferred
olmesartan tabs	valsartan solution
telmisartan tabs	Teveten® tabs
valsartan tabs ¹	

- ¹ Added as “Preferred”
² Moved to “Non-Preferred”
** Prior Authorization required

5. Old Business
None

6. New Business
Dr. Wessinger, Chief Medical Officer, provided an overview of the criteria for approval of Wegovy® MACE (Major Adverse Cardiovascular Events). Depending upon SC budget approval, coverage of CGMs (Continuous Glucose Monitors) may be expanded based upon criteria to include a beneficiary having T1DM, gestational diabetes or Type 2 diabetes with any type of insulin dependency or recurrent moderate (Level 2) or one severe (Level 3) hypoglycemic event. Cheryl Anderson, RPh, introduced 4 new P&T Committee members.

Lisa Correll presented new drugs to market. Pharma meetings are offered for 1 entity per year and remain virtual in 2024.

7. Actions of the P&T Committee

Classes for Review

- HIV/AIDS (*Effective 10/1/2024*)
- Atopic Dermatitis Immunomodulators, Injectables (*Effective 10/1/2024*)
- Weight Management Agents, Injectables (*Approved pending legislative budgetary approval*)

Classes for Re-review

- Angiotensin Receptor Blockers (ARBs) (*Effective 7/01/2024*)

8. Closing Comments

The next meeting will be held Wednesday, August 7, 2024 at 4pm.

9. Adjournment

The meeting adjourned at 4:20 pm.